Description
The global interventional radiology market is experiencing steady expansion as healthcare systems increasingly shift toward minimally invasive, image-guided approaches for diagnosing and treating complex conditions. The market was estimated at USD 30.9 billion in 2025 and is projected to reach USD 51.5 billion by 2035, registering a CAGR of 5.2% during 2026–2035. Growth is primarily supported by the rising prevalence of chronic diseases, particularly cardiovascular disorders, cancer, and other conditions requiring targeted interventions, alongside an aging global population. Interventional radiology enables physicians to diagnose and treat diseases using image-guided techniques, often reducing procedural trauma, recovery time, and hospital stays compared with conventional surgery. Technological progress in medical imaging is further strengthening adoption. Modern angiography systems increasingly incorporate flat-panel detectors, cone-beam CT, three-dimensional roadmaps, image fusion, and advanced visualization capabilities, improving anatomical visualization and procedural navigation. CT and MRI systems are also expanding their role in image-guided biopsies, tumor ablation, drainage procedures, and treatment planning, while ultrasound is gaining traction in vascular access, biopsies, drainage, ablation, and therapeutic procedures. These developments are broadening the clinical applications of interventional radiology beyond traditional vascular interventions.
The market is also being shaped by the convergence of imaging, artificial intelligence, robotics, and minimally invasive therapeutic technologies. AI-assisted image analysis, automated anatomical recognition, needle trajectory planning, procedural guidance, and workflow optimization are creating opportunities to improve precision and reduce operator variability. Healthcare providers are additionally investing in hybrid operating rooms that combine advanced imaging with surgical capabilities, supporting complex cardiovascular, neurovascular, and oncological procedures that require multidisciplinary intervention. Growing concern regarding cumulative radiation exposure is encouraging manufacturers and healthcare institutions to develop dose-reduction technologies, radiation-monitoring solutions, and radiation-free imaging alternatives. North America currently represents the largest regional market, supported by advanced healthcare infrastructure, high procedure volumes, established reimbursement systems, and early adoption of innovative imaging technologies, while Asia Pacific is identified as the fastest-growing region, supported by expanding healthcare access, infrastructure modernization, medical tourism, and the increasing burden of chronic diseases. Hospitals remain the leading end-use setting because of their ability to support complex procedures, multidisciplinary teams, advanced imaging infrastructure, and emergency care. At the same time, the shift from inpatient toward outpatient care is creating opportunities for clinics and ambulatory surgical centers. High equipment costs and complex regulatory requirements remain key constraints, particularly for smaller healthcare facilities and cost-sensitive markets.
Key Highlights of the Report
• Angiography systems represent the leading product segment, supported by their extensive use in vascular, cardiovascular, neurovascular, and oncological interventions.
• Ultrasound imaging systems are expected to witness strong growth, driven by their expanding use in biopsies, vascular access, drainage, ablation, and other image-guided procedures.
• CT scanners remain important for both diagnostic planning and procedural guidance, particularly in biopsies, drain placements, and ablation procedures.
• MRI systems are gaining importance in interventional oncology, particularly where superior soft-tissue visualization and radiation-free imaging provide clinical advantages.
• Fluoroscopy systems continue to support minimally invasive interventions, particularly in vascular and gastrointestinal procedures.
• Biopsy devices remain an important component of the interventional radiology ecosystem, supporting image-guided tissue sampling across multiple disease areas.
• Cardiology is the leading application segment, supported by the high prevalence of cardiovascular disease and established interventional treatment pathways.
• Oncology represents a major growth opportunity, driven by increasing use of tumor ablation, embolization, image-guided biopsies, and other interventional oncology procedures.
• Hospitals dominate the end-use segment, benefiting from specialized infrastructure, multidisciplinary teams, emergency capabilities, and established referral networks.
• Clinics are expanding their role in interventional radiology, particularly as healthcare systems move selected procedures toward outpatient settings.
• Ambulatory surgical centers provide an emerging growth channel, supported by the broader shift toward shorter-stay and outpatient procedures.
• Rising chronic disease prevalence remains the principal market driver, particularly cardiovascular disease and cancer.
• Technological advances in medical imaging are expanding the clinical capabilities of IR, particularly through 3D/4D imaging, image fusion, cone-beam CT, advanced navigation, and AI-assisted workflows.
• Increasing demand for minimally invasive procedures is supporting adoption, as patients and providers seek procedures associated with reduced trauma and faster recovery.
• The growing elderly population is increasing procedural demand, particularly for vascular, oncological, and other chronic disease interventions.
• AI- and robotics-enabled image-guided interventions represent a major opportunity, with applications in image interpretation, navigation, trajectory planning, and procedural assistance.
• Investment in hybrid operating rooms is increasing, particularly for complex cardiovascular, neurovascular, and oncological interventions.
• Low-radiation and radiation-free imaging technologies are emerging as important innovation areas, addressing occupational and patient exposure concerns.
• The inpatient-to-outpatient shift is creating new opportunities, particularly for clinics and ambulatory surgical centers with appropriate infrastructure.
• High equipment costs remain a major challenge, potentially limiting adoption among smaller hospitals and facilities in developing markets.
• Complex regulatory requirements can delay commercialization and adoption of new technologies, increasing compliance and development costs.
• North America remains the largest regional market, supported by advanced healthcare infrastructure, established reimbursement frameworks, high procedure volumes, and early technology adoption.
• Asia Pacific is the fastest-growing regional market, driven by expanding healthcare access, infrastructure modernization, medical tourism, and rising chronic disease prevalence.
• China represents a major growth market in Asia Pacific, supported by healthcare investment, hospital modernization, expanding insurance coverage, and demand for minimally invasive therapies.
• India offers significant long-term potential, supported by expanding healthcare coverage, infrastructure development, and increasing adoption of advanced medical technologies.
• Europe represents a significant established market, with Germany, the UK, France, Spain, Italy, and the Netherlands serving as important markets.
• Brazil leads the Latin American market, supported by increasing healthcare infrastructure and demand for cardiovascular, oncological, and minimally invasive procedures.
• Saudi Arabia represents an important Middle East opportunity, supported by healthcare modernization, investment in advanced hospitals, and increasing demand for minimally invasive treatment.
• Koninklijke Philips is identified as the market leader, with more than 22% market share in 2025. Canon Medical Systems, Fujifilm Corporation, GE Healthcare, Koninklijke Philips, and Siemens Healthineers are the leading players, collectively accounting for approximately 58% of the market in 2025.
Key Company Profiles
• Agfa-Gevaert Group
• Canon Medical Systems
• Carestream Health Inc.
• Esaote SPA
• Fujifilm Corporation
• GE Healthcare
• Koninklijke Philips
• Olympus Corporation
• Samsung Healthcare
• Shimadzu Corporation
Data Source
Apelo Consulting employs comprehensive primary and secondary research techniques in developing distinctive data sets and research material for business reports. This report is built by using data and information sourced from Proprietary Information Database, Primary and Secondary Research Methodologies, and In house analysis by Apelo Consulting dedicated team of qualified professionals with deep industry experience and expertise.
